{"id":"NCT02009865","sponsor":"AstraZeneca","briefTitle":"Epanova® for Lowering Very High Triglycerides II (EVOLVE II)","officialTitle":"A 12-Week, Randomized, Double-Blind, Olive Oil-Controlled Phase 3 Study to Assess the Efficacy and Safety of EPANOVA™ in Subjects With Severe Hypertriglyceridemia (EVOLVE II)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-12-16","primaryCompletion":"2014-12-23","completion":"2014-12-23","firstPosted":"2013-12-12","resultsPosted":"2016-01-15","lastUpdate":"2019-09-10"},"enrollment":379,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Hypertriglyceridemia"],"interventions":[{"type":"DRUG","name":"Epanova","otherNames":["omega-3 free fatty acids"]},{"type":"DRUG","name":"Olive Oil","otherNames":["placebo comparator"]}],"arms":[{"label":"Epanova 2 g/day","type":"EXPERIMENTAL"},{"label":"Olive Oil 2 g/day","type":"PLACEBO_COMPARATOR"}],"summary":"This is a double-blind, randomized, olive oil-controlled study to investigate the efficacy and safety of Epanova as an adjunct therapy to diet for reduction of TG levels in subjects with severe hypertriglyceridemia. The study consists of an approximately 8-week screening period that includes a diet and lifestyle stabilization and washout period and a 12-week treatment period.","primaryOutcome":{"measure":"Percent Change in Triglyceride for All Subjects","timeFrame":"From Baseline to Week 12 Endpoint","effectByArm":[{"arm":"Epanova","deltaMin":-28.1,"sd":null},{"arm":"Olive Oil","deltaMin":-10.2,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.017"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":40,"countries":["United States","Canada","Czechia","Denmark","Hungary","Netherlands","Russia"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":81},"commonTop":["All","ALL","Diarrhoea","ALL","ALL"]}}